A bird flu outbreak could spur demand for vaccines from these key players, but is it likely?
The vaccine maker's recovery story is looking brighter.
The biotech still hasn't lost momentum.
Sanofi believes in Novavax's vaccine strengths...
These two healthcare stocks may be deeply undervalued.
Novavax shares have soared and plummeted in recent years.
Moderate success regarding a new licensing deal with Sanofi could make the troubled vaccine stock a top performer.
A cloud of doubt hanging over the company just gave way to some sunshine.
Investors should expect a modest 2024 before seeing more exciting returns for the drugmaker in 2025 following the expected approval of rilzabrutinib.
It pays to develop novel medicines for life-threatening illnesses.